LIVER CIRRHOSIS IN ADULT MEN: AN INTEGRATIVE REVIEW
DOI:
https://doi.org/10.56238/arev8n3-049Keywords:
Liver Cirrhosis, Mortality, Hepatic Decompensation, Systemic Inflammation, PrognosisAbstract
Liver cirrhosis is a chronic and progressive disease associated with high morbidity and mortality, particularly among adult men. It is characterized by structural and functional liver alterations and may progress to decompensated events, organ failure, and death. This study aimed to analyze scientific evidence on liver cirrhosis in adult male individuals, focusing on clinical outcomes and prognostic factors. This integrative literature review was conducted using the PubMed/MEDLINE, SciELO, LILACS and Google Scholar databases, including articles published between 2019 and 2026. After applying inclusion and exclusion criteria, 19 studies were selected. The findings demonstrated high mortality associated with cirrhosis, especially in the presence of alcohol consumption, acute kidney injury, infections, systemic inflammation, sarcopenia, and frailty. Disease progression was not solely related to baseline liver function but also to the occurrence of new decompensation events during hospitalization. In conclusion, liver cirrhosis in adult men should be understood as a systemic condition, requiring a multidimensional clinical approach and early interventions to reduce complications and mortality.
Downloads
References
DONG, L.; XIAO, Y.; LI, Y.; HE, Y.; LIU, Y.; QI, X.; WANG, H. hs-cTnT and NT-ProBNP, rather than unspecified coronary artery disease, may be associated with further decompensation and death in liver cirrhosis. Digestive and Liver Disease, v. 57, n. 12, p. 2399–2409, 2025. DOI: 10.1016/j.dld.2025.09.019. DOI: https://doi.org/10.1016/j.dld.2025.09.019
EIFLER, L. M.; MOREIRA, T. R.; POSSEBON, J. P. P.; FERREIRA, L. F.; JOTZ, R. F.; MATTOS, Â. Z. Impact of sarcopenia on the prognosis of patients with cirrhosis hospitalized for acute decompensation or acute-on-chronic liver failure. Arquivos de Gastroenterologia, v. 61, e24069, 2024. DOI: 10.1590/S0004-2803.24612024-069. DOI: https://doi.org/10.1590/s0004-2803.24612024-069
FULLER, H.; TITTANEGRO, T. H.; MAINI, A. A.; CHINA, L.; RHODES, F.; BECARES SALLES, N.; MUKHOPADHYAY, S.; MOORE, B.; O’BRIEN, A. Hyperbilirubinemia at hospitalization predicts nosocomial infection in decompensated cirrhosis: data from ATTIRE trial. Hepatology Communications, v. 9, n. 4, e0648, 2025. DOI: 10.1097/HC9.0000000000000648. DOI: https://doi.org/10.1097/HC9.0000000000000648
HANAI, T.; NISHIMURA, K.; UNOME, S. et al. Alcohol-associated liver disease increases the risk of muscle loss and mortality in patients with cirrhosis. Journal of Gastroenterology, v. 59, p. 932–940, 2024. DOI: 10.1007/s00535-024-02137-4. DOI: https://doi.org/10.1007/s00535-024-02137-4
HARTL, L.; HINTERSTEININGER, M.; SIMBRUNNER, B. et al. The vasopressin biomarker copeptin is linked to systemic inflammation and refines prognostication in decompensated cirrhosis. Clinical Gastroenterology and Hepatology, v. 24, n. 1, p. 131–140, 2026. DOI: 10.1016/j.cgh.2025.04.030. DOI: https://doi.org/10.1016/j.cgh.2025.04.030
KABELITZ, M. A.; GAIRING, S. J.; TIEDE, A. et al. Impact of frailty on the prognosis of patients with liver cirrhosis undergoing insertion of a TIPS. Alimentary Pharmacology & Therapeutics, v. 63, n. 1, p. 109–118, 2026. DOI: 10.1111/apt.70315. DOI: https://doi.org/10.1111/apt.70315
KOSUTA, I.; BABEL, J.; DOMISLOVIC, V. et al. Clinical impact of multidrug-resistant organisms in liver cirrhosis: a retrospective cohort study in the intensive care setting. World Journal of Gastroenterology, v. 31, n. 39, p. 111261, 2025. DOI: 10.3748/wjg.v31.i39.111261. DOI: https://doi.org/10.3748/wjg.v31.i39.111261
LAN, Y.; YU, Y.; ZHANG, X. et al. Risk factors and prognostic impact of new decompensated events in hospitalized patients with decompensated cirrhosis. BMC Gastroenterology, v. 24, n. 1, p. 408, 2024. DOI: 10.1186/s12876-024-03494-3. DOI: https://doi.org/10.1186/s12876-024-03494-3
MIWA, T.; UTAKATA, Y.; HANAI, T. et al. Acute kidney injury development is associated with mortality in Japanese patients with cirrhosis: impact of amino acid imbalance. Journal of Gastroenterology, v. 59, p. 849–857, 2024. DOI: 10.1007/s00535-024-02126-7. DOI: https://doi.org/10.1007/s00535-024-02126-7
MO, R.; ZHANG, Z.; ZHOU, Y. et al. A new prognostic model based on serum apolipoprotein AI in patients with HBV-ACLF and acutely decompensated liver cirrhosis. Lipids in Health and Disease, v. 24, n. 1, p. 35, 2025. DOI: 10.1186/s12944-025-02434-8. DOI: https://doi.org/10.1186/s12944-025-02434-8
PEARSON, M. M.; KIM, N. J.; BERRY, K. et al. Associations between alcohol use and liver-related outcomes in a large national cohort of patients with cirrhosis. Hepatology Communications, v. 5, n. 12, p. 2080–2095, 2021. DOI: 10.1002/hep4.1776. DOI: https://doi.org/10.1002/hep4.1776
SCHLEICHER, E. M.; KAPS, L.; SCHATTENBERG, J. M. et al. Higher scores in the Clinical Frailty Scale are associated with covert and overt hepatic encephalopathy in patients with cirrhosis. Digestive and Liver Disease, v. 56, n. 6, p. 1046–1053, 2024. DOI: 10.1016/j.dld.2023.12.001. DOI: https://doi.org/10.1016/j.dld.2023.12.001
SHIN, S. K.; YIM, H. J.; KIM, J. H. et al. Partial virological response after 2 years of entecavir therapy increases the risk of hepatocellular carcinoma in patients with hepatitis B virus-associated cirrhosis. Gut and Liver, v. 15, n. 3, p. 430–439, 2021. DOI: 10.5009/gnl20074. DOI: https://doi.org/10.5009/gnl20074
TIEDE, A.; STOCKHOFF, L.; LIU, Z. et al. Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis. Clinical and Molecular Hepatology, v. 31, n. 1, p. 240–255, 2025. DOI: 10.3350/cmh.2024.0587. DOI: https://doi.org/10.3350/cmh.2025.0135
VÉLEZ, J. L.; PÉREZ, A.; BLANCO, J. D. et al. Caracterización de los pacientes con cirrosis agudamente descompensada que consultaron a diferentes servicios de urgencias de alta complejidad en Medellín, Colombia. Biomédica, v. 43, supl. 3, p. 9–20, 2023.
WENTWORTH, B. J.; GENG, C. X.; NOVICOFF, W. M.; SIRAGY, H. M.; HENRY, Z. H. Adrenal dysfunction in outpatients with decompensated cirrhosis: impairment in the hypothalamic-pituitary-adrenal axis. Digestive Diseases and Sciences, v. 70, n. 12, p. 4247–4258, 2025. DOI: 10.1007/s10620-025-09237-y. DOI: https://doi.org/10.1007/s10620-025-09237-y
WONG, R. J.; JONES, P. D.; NIU, B. et al. Hepatocellular carcinoma surveillance in patients with cirrhosis at US safety-net health systems. Clinical and Translational Gastroenterology, v. 16, n. 8, e00877, 2025. DOI: 10.14309/ctg.0000000000000877. DOI: https://doi.org/10.14309/ctg.0000000000000877
YILMA, M.; KIM, N. J.; SHUI, A. M. et al. Factors associated with liver transplant referral among patients with cirrhosis at multiple safety-net hospitals. JAMA Network Open, v. 6, n. 6, e2317549, 2023. DOI: 10.1001/jamanetworkopen.2023.17549. DOI: https://doi.org/10.1001/jamanetworkopen.2023.17549
ZHANG, X.; ZHAO, L.; DAI, Q. et al. Blood magnesium level and risk of hepatocellular carcinoma in a prospective liver cirrhosis cohort. Cancer Epidemiology, Biomarkers & Prevention, v. 33, n. 10, p. 1368–1374, 2024. DOI: 10.1158/1055-9965.EPI-24-0327. DOI: https://doi.org/10.1158/1055-9965.EPI-24-0327
